Displaying drugs 10951 - 10975 of 11681 in total
Oleclumab
Oleclumab is under investigation in clinical trial NCT03819465 (A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC).
Investigational
Matched Description: … Oleclumab is under investigation in clinical trial NCT03819465 (A Study of Novel Anti-cancer Agents in …
Molidustat
Molidustat is under investigation in clinical trial NCT03350321 (A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects).
Investigational
Matched Description: … Molidustat is under investigation in clinical trial NCT03350321 (A Study of Molidustat for Correction …
GW810781
GW810781 is under investigation in clinical trial NCT00046332 (A Study Comparing 4 Doses of GW810781 Versus Placebo in Hiv-infected Patients).
Investigational
Matched Description: … GW810781 is under investigation in clinical trial NCT00046332 (A Study Comparing 4 Doses of GW810781 …
OPB-111077
OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation. It has demonstrated promising anticancer activity in preclinical models.
Investigational
Matched Description: … OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation. …
JZP-386 free base
JZP-386 is a deuterium-containing analog of sodium oxybate. Its safety, pharmacokinetics and pharmacodynamics were evaluated in clinical trial NCT02215499.
Investigational
Matched Description: … JZP-386 is a deuterium-containing analog of sodium oxybate. …
LV305
LV305 is a lentiviral vector encoding NY-ESO-1 gene. LV305 is an active component of CMB305 along with G305.
Investigational
Matched Description: … LV305 is a lentiviral vector encoding NY-ESO-1 gene. …
KAHR-102
KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).
Investigational
Matched Description: … KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the …
OTOF-GT
OTOF-GT is a dual vector AAV gene therapy being investigated for the restoration of hearing loss associated with otoferlin deficiency.
Investigational
Matched Description: … OTOF-GT is a dual vector AAV gene therapy being investigated for the restoration of hearing loss associated …
GX-G8
GX-G8 is a long-acting glucagon-like peptide 2 (GLP-2) being investigated for the treatment of short bowel syndrome.
Investigational
Matched Description: … GX-G8 is a long-acting glucagon-like peptide 2 (GLP-2) being investigated for the treatment of short …
Remternetug
Remternetug is under investigation in clinical trial NCT05463731 (A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)).
Investigational
Matched Description: … Remternetug is under investigation in clinical trial NCT05463731 (A Study of Remternetug (LY3372993) …
Phosphatidyl serine
Phosphatidyl serine (PS) is a phospholipid nutrient found in fish, green leafy vegetables, soybeans and rice, and is essential for the normal functioning of neuronal cell membranes and activates Protein kinase C (PKC) which has been shown to be involved in memory function. In apoptosis, phosphatidyl serine is transferred to...
Investigational
Nutraceutical
Matched Description: … Phosphatidyl serine (PS) is a phospholipid nutrient found in fish, green leafy vegetables, soybeans and ... Because of the potentail cognitive benefits of phosphatidylserine, the substance is sold as a dietary ... PS has been investigated in a small number of double-blind placebo trials and has been shown to increase …
NM-702
Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis obliterans.
M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. In Japan, Phase 2 studies are being conducted for intermittent claudication caused by arteriosclerosis obliterans, intermittent claudication caused by spinal canal stenosis,...
Investigational
Matched Description: … Intermittent claudication is a major symptom of arteriosclerosis obliterans. ... Nissan Chemical and Taisho have been jointly developing NM-702, a drug for the treatment of arteriosclerosis ... In the USA, a Phase 2 study for intermittent claudication caused by arteriosclerosis obliterans has been …
Beraprost
Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.
Investigational
Matched Description: … Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary …
Palifosfamide
Palifosfamide (ZIO-201) is a proprietary stabilized metabolite of ifosfamide. Ifosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.
Investigational
Matched Description: … Palifosfamide (ZIO-201) is a proprietary stabilized metabolite of ifosfamide. …
siG12D LODER
siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer).
Investigational
Matched Description: … siG12D LODER is under investigation in clinical trial NCT01676259 (A Phase 2 Study of Sig12d LODER in …
IMMU-114
IMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker.
Investigational
Matched Description: … consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a …
Nalorphine
Nalorphine is a mixed opioid agonist–antagonist. It acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics. It is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to determine opioid dependence.
Experimental
Vet approved
Matched Description: … Nalorphine is a mixed opioid agonist–antagonist. ... It is used to reverse opioid overdose and (starting in the 1950s) in a challenge test to determine opioid …
XAV-19
XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody that targets the spike protein of SARS-CoV-2[L16553,L16558]. The therapy offers three beneficial effects: the ability...
Investigational
Matched Description: … However, rather than using human plasma, XAV-19 is a heterologous swine glyco-humanized polyclonal antibody ... As of July, 2020, the company is conducting a Phase 2 randomized clinical trial to define dosing safety ... Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University …
Tasosartan
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.
Experimental
Matched Description: … Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. …
Patupilone
Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.
Experimental
Investigational
Matched Description: … Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol. …
Bivatuzumab
Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6. [A31688,A31689]
Investigational
Matched Description: … Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6. [A31688,A31689] …
Seratrodast
Seratrodast (INN) is a thromboxane receptor antagonist used primarily in the treatment of asthma.
Experimental
Matched Description: … Seratrodast (INN) is a thromboxane receptor antagonist used primarily in the treatment of asthma. …
Displaying drugs 10951 - 10975 of 11681 in total